To investigate the impact of diabetic status on 2-year clinical outcomes in Chinese patients undergoing contemporary percutaneous coronary intervention (PCI) treatment.
Methods and Results:
A total of 10 724 consecutive patients underwent PCI at Fu Wai Hospital were prospectively collected. Two-year clinical outcomes were compared between patients with and without diabetes mellitus (DM). Diabetic patients had more baseline clinical risks and more extensive coronary disease. During 2-year follow-up, the rates of all-cause death, myocardial infarction (MI), revascularization, and major adverse cardiac events (MACE) were significantly higher in DM group. After multivariable-adjusted Cox regression analysis, DM was an independent risk factor for MACE but not for the individual components of MACE. After performing propensity score matching, rates of all-cause death, MI, revascularization, stroke, stent thrombosis, and MACE were not significantly different between the 2 groups, and DM was not predictive of MACE and any clinical adverse outcomes.
Conclusions:
Diabetic patients who underwent PCI had worse prognosis including death and repeat revascularization during 2-year follow-up, but DM was not an independent risk factor for adverse clinical outcomes.
ZhengXCurtisJPHuS. Coronary catheterization and percutaneous coronary intervention in China: 10-year results from the China PEACE-Retrospective CathPCI Study. JAMA Intern Med. 2016;176:512–21. doi:10.1001/jamainternmed.2016.0166
2.
EleziSKastratiAPacheJ. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998;32:1866–73.
3.
FlahertyJDDavidsonCJ. Diabetes and coronary revascularization. JAMA. 2005;293:1501–8.
4.
BillingerMRaberLHitzS. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am Heart J. 2012;163:876–86.
5.
RoffiMAngiolilloDJKappeteinAP. Current concepts on coronary revascularization in diabetic patients. Eur Heart J. 2011;32:2748–57. doi:10.1093/eurheartj/ehr305
6.
HermillerJBRaiznerACannonL. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1172–9.
7.
MahmudEOrmistonJATurcoMA. TAXUS Liberté attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. JACC Cardiovasc Interv. 2009;2:240–52. doi:10.1016/j.jcin.2008.12.009
8.
MoussaILeonMBBaimDS. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273–8.
9.
JensenLOMaengMThayssenP. Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in Western Denmark. Am J Cardiol. 2010;105:1513–9.
10.
BangaloreSKumarSFusaroM. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomized trials. BMJ. 2012;345:e5170.
11.
FranzoneAPilgrimTHegD. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. Circ Cardiovasc Interv. 2015;8:pii:e002319. doi:10.1161/CIRCINTERVENTIONS.114.002319
12.
KedhiEGénéreuxPPalmeriniT. Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. J Am Coll Cardiol. 2014;63:2111–8. doi:10.1016/j.jacc.2014.01.064
13.
KoskinasKCSiontisGCPiccoloR. Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients. Circ Cardiovasc Interv. 2016;9:e003255. doi:10.1161/CIRCINTERVENTIONS.115.003255
14.
ParkDWParkSWParkKH. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352–6.
15.
XuBLiJJYangYJ. A single center investigation of bare-metal or drug-eluting stent restenosis from 1633 consecutive Chinese Han ethnic patients. Chin Med J (Engl). 2006;119:533–8.
16.
ParkDWFlahertyJDDavidsonCJ. Prognostic influence of diabetes mellitus on long-term clinical outcomes and stent thrombosis after drug-eluting stent implantation in Asian patients. Am J Cardiol. 2009;103:646–52. doi:10.1016/j.amjcard.2008.11.012
17.
JaffeAS. Third universal definition of myocardial infarction. Clin Biochem. 2013;46:1–4.
18.
CutlipDEWindeckerSMehranR. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.
19.
PreisSRPencinaMJHwangSJ. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009;120:212–20.
20.
CreagerMALüscherTFCosentinoFBeckmanJA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527–32. doi:10.1161/01.CIR.0000091257.27563.32
21.
Biondi-ZoccaiGGAbbateALiuzzoGBiasucciLM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol. 2003;41:1071–7.
22.
KedhiEJoesoefKSMcFaddenE. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375:201–9. doi:10.1016/S0140-6736(09)62127-9
23.
StoneGWMideiMNewmanW. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903–13. doi:10.1001/ jama.299.16.1903
24.
StoneGWRizviANewmanW. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663–74. doi:10.1056/NEJMoa0910496
25.
StefaniniGGByrneRASerruysPW. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214–22. doi:10.1093/eurheartj/ehs086
26.
StegmanBPuriRChoL. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care. 2014;37:3114–20. doi:10.2337/dc14-1121
27.
FarooqVvan KlaverenDSteyerbergEW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381:639–50. doi:10.1016/S0140-6736(13)60108-7
28.
FarkouhMEDomanskiMSleeperLA. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;20;367:2375–84. doi:10.1056/NEJMoa1211585
